Screener
Avalo Therapeutics AVTX Prepaid & Other Current
Prepaid & Other Current at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's prepaid & other current?
- Avalo Therapeutics (AVTX) reported prepaid & other current of $7.61M in Q2 2026.
- How has Avalo Therapeutics's prepaid & other current changed year-over-year?
- Avalo Therapeutics's prepaid & other current increased by 299.7% year-over-year, from $1.9M to $7.61M.
- What is the long-term trend for Avalo Therapeutics's prepaid & other current?
- Over 5 years (2020 to 2025), Avalo Therapeutics's prepaid & other current has grown at a 21.0% compound annual growth rate (CAGR), from $2.66M to $6.91M.
- What does prepaid & other current mean?
- Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.
Ask your AI about Avalo Therapeutics's prepaid & other current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude